These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17252257)

  • 1. [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].
    Semler O; Land C; Schönau E
    Orthopade; 2007 Feb; 36(2):146-51. PubMed ID: 17252257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bisphosphonates in osteoporosis therapy. Standards and perspectives].
    Reinsdorf S; Habermann B; Hochmuth K; Kurth AA
    Orthopade; 2007 Feb; 36(2):110-7. PubMed ID: 17252258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.
    Wagner S; Poirot I; Vuillerot C; Berard C
    Ann Phys Rehabil Med; 2011 Sep; 54(6):348-58. PubMed ID: 21840280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
    Nasomyont N; Hornung LN; Gordon CM; Wasserman H
    Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biphosphonates and osteogenesis imperfecta in children].
    Gandon-Laloum S
    Arch Pediatr; 2009 Jul; 16(7):1085-9. PubMed ID: 19423303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
    Aström E; Söderhäll S
    Arch Dis Child; 2002 May; 86(5):356-64. PubMed ID: 11970931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone diseases with Pain. Osteoporosis].
    Hayashi Y
    Clin Calcium; 2007 Apr; 17(4):606-12. PubMed ID: 17404492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.